Lundbeckfond Ventures, Seventure and Ipsen have taken part in a series-C round of financing for biopharmaceutical company Syntaxin.
This article is only available to subscribers to unquote.com. Subscribers just need to log in below for immediate access. Not a subscriber? Sign up now for immediate free trial access
Sign up
Free trial
Try unquote.com free for 2 weeks. A trial will give you access to the entire site.